扩大初始评估分子检测的推荐人群 小细胞肺癌(SCLC, small cell lung cancer)约占所有肺癌患者的1/4,据统计全球每年有近25万的SCLC新发病例。由于其高侵袭性及易转移的特点,近2/3的患者在诊断初期就已为广泛期小细胞肺癌(ES-SCLC),从而失去了手术机会。化疗是ES-SCLC的标准治疗方案,但ES-SCLC中位总生存期(OS)...
and supported by funding from NCCN Foundation® ® These NCCN Guidelines for Patients are based on the NCCN Guidelines for Small Cell Lung Cancer, Version 1.2022 – August 9, 2021. © 2021 National Comprehensive Cancer Network, Inc . All rights reserved. NCCN Foundation seeks to support ...
[1]NCCN Guidelines Version 4.2024 Non-Small Cell Lung Cancer. [2]2022.《NCCN肿瘤学临床实践指南:非小细胞肺癌》 [3] FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer | FDA https://www.fda.gov/ne...
CA Cancer J Clin, 2021, 71(3): 209-249. 2. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med, 2021, 27(8): 1345-1356. 3. NCCN non-small cell lung cancer panel members. NCCN guidelines for non-small cell lung ...
2023.v3 NCCN临床实践指南:小细胞肺癌.pdf,® NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Small Cell Lung Cancer Version 3.2023 — December 21, 2022 NCCN.org ® NCCN Guidelines for Patients available at /patients Continue ® ®
❖适用于完全切除的 II 至 IIIB 期非小细胞肺癌(NSCLC)患者,这些患者之前接受了新辅助纳武利尤单抗 + 化疗,且无已知的 EGFR 突变或 ALK 重排(类别 1)。 [1]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Non-Small Cell Lung Cancer, Version 11.2024, October 15, 2024....
The 20th Annual Edition of the National Comprehensive Cancer Network ( NCCN ) Guidelines for small-cell lung cancer ( SCLC ) have been issued. This guideline is one of the eight original NCCN Guidelines published initially in November 1996. NCCN Guidelines Panel Chair for SCLC DrGreg Kalem...
CA Cancer J Clin, 2021, 71(3): 209-249. 2. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med, 2021, 27(8): 1345-1356. 3. NCCN non-small cell lung cancer panel members. NCCN guidelines for non-small cell lung ...
SIGNS AND SYMPTOMS OF SMALL CELL LUNG CANCER 由于局部原发性肿瘤生长导致的体征和症状咳嗽——支气管内刺激、支气管压迫咯血-通常为中心或空洞病变喘息-部分阻塞支气管内病变发热-术后肺炎呼吸困难-支气管阻塞、肺炎、胸腔积液由于原发肿瘤侵袭或局部淋巴转移引起的体征和症状声嘶——主肺动脉窗肿瘤侵袭或淋巴结肿大...
[3] FDA approves larotrectinib for solid tumors with NTRK gene fusions [4] FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusi...